Sarcopenia — a progressive loss of muscle mass, strength and function — has generally been associated with advanced aging, ...

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule ...

Last year, Sarepta – which leads the market for exon-skipping DMD drugs – got FDA approval for Elevidys (delandistrogene moxeparvovec), the first gene therapy for the muscle-wasting disease.